A Randomized Phase II Study to Evaluate the Effect of Two Different Doses of Enoxaparin Sodium in Combination With Standard Chemotherapy (Cisplatin Plus Etoposide) With Respect to Time to Tumor Progression (TTP) in Patients With Newly Diagnosed Extensive Stage Small Cell Lung Cancer (SCLC) Without Underlying Venous Thromboembolism

Trial Profile

A Randomized Phase II Study to Evaluate the Effect of Two Different Doses of Enoxaparin Sodium in Combination With Standard Chemotherapy (Cisplatin Plus Etoposide) With Respect to Time to Tumor Progression (TTP) in Patients With Newly Diagnosed Extensive Stage Small Cell Lung Cancer (SCLC) Without Underlying Venous Thromboembolism

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 07 May 2013

At a glance

  • Drugs Enoxaparin sodium (Primary) ; Cisplatin; Etoposide
  • Indications Small cell lung cancer
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 07 May 2013 Status changed from suspended to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 06 Jul 2010 Status changed from active, no longer recruiting to suspended as reported by ClinicalTrials.gov.
    • 23 Jun 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top